(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.02%) 15 928 points
(-0.80%) $83.18
(1.04%) $1.943
(-0.30%) $2 340.20
(0.05%) $27.55
(0.67%) $928.30
(-0.19%) $0.933
(-0.20%) $11.00
(-0.27%) $0.798
(0.25%) $92.11
0.00% $ 1.100
@ $1.160
Wydano: 14 vas. 2024 @ 16:35
Zwrot: -5.17%
Poprzedni sygnał: vas. 13 - 16:30
Poprzedni sygnał:
Zwrot: 0.00 %
Live Chart Being Loaded With Signals
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases...
Stats | |
---|---|
Dzisiejszy wolumen | 351 535 |
Średni wolumen | 1.47M |
Kapitalizacja rynkowa | 192.92M |
EPS | $0 ( 2024-03-05 ) |
Następna data zysków | ( $-0.0300 ) 2024-05-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -7.86 |
ATR14 | $0.00300 (0.28%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-27 | Rojkjaer Lisa | Buy | 187 500 | Employee Stock Option (right to buy) |
2024-03-27 | Rojkjaer Lisa | Buy | 0 | |
2024-02-28 | Schorno Dean L | Buy | 78 500 | Employee Stock Option (right to buy) |
2024-02-28 | Schorno Dean L | Buy | 62 500 | Employee Stock Option (right to buy) |
2024-02-28 | Santos David A | Buy | 80 000 | Employee Stock Option (right to buy) |
INSIDER POWER |
---|
93.23 |
Last 98 transactions |
Buy: 9 654 000 | Sell: 304 047 |
Wolumen Korelacja
Rigel Pharmaceuticals Inc Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
CRNC | 0.963 |
ROIV | 0.959 |
NLSP | 0.958 |
MLCO | 0.954 |
MOMO | 0.954 |
FXCO | 0.951 |
CTSO | 0.949 |
APAC | 0.948 |
VRDN | 0.946 |
BRAC | 0.945 |
10 Najbardziej negatywne korelacje | |
---|---|
GRIN | -0.954 |
PIII | -0.939 |
RIVN | -0.938 |
SNPX | -0.925 |
OP | -0.924 |
SWAV | -0.923 |
ZENV | -0.923 |
LAWS | -0.919 |
NAKD | -0.916 |
ENPH | -0.916 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Rigel Pharmaceuticals Inc Korelacja - Waluta/Towar
Rigel Pharmaceuticals Inc Finanse
Annual | 2023 |
Przychody: | $116.88M |
Zysk brutto: | $109.77M (93.92 %) |
EPS: | $-0.140 |
FY | 2023 |
Przychody: | $116.88M |
Zysk brutto: | $109.77M (93.92 %) |
EPS: | $-0.140 |
FY | 2022 |
Przychody: | $120.24M |
Zysk brutto: | $118.49M (98.55 %) |
EPS: | $-0.360 |
FY | 2021 |
Przychody: | $149.24M |
Zysk brutto: | $148.15M (99.27 %) |
EPS: | $-0.110 |
Financial Reports:
No articles found.
Rigel Pharmaceuticals Inc
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej